IgA nephropathy

Patients should undergo routine testing according to local guidelines for management of chronic kidney disease, which universally include monitoring of estimated glomerular filtration rate (GFR) and degree of proteinuria. Patients receiving renin angiotensin system inhibitors should be monitored for hyperkalemia and a decline in GFR when starting treatment, and with any adjustment in dose. Patients taking immunosuppressants should be routinely evaluated for complications of treatment. This should include monitoring for leukopenia, impaired glucose tolerance, and liver function and electrolyte abnormalities.